Willis Zachary I, Nicholson Maribeth R, Esbenshade Adam J, Xu Meng, Slaughter James C, Friedman Debra L, Edwards Kathryn M, Di Pentima Maria C
Department of Pediatrics, Division of Pediatric Infectious Diseases, University of North Carolina School of Medicine, Chapel Hill, NC.
Departments of Pediatrics, D. Brent Polk Division of Gastroenterology, Hepatology, and Nutrition.
J Pediatr Hematol Oncol. 2019 Aug;41(6):442-447. doi: 10.1097/MPH.0000000000001411.
Clostridium difficile infection (CDI) is common in pediatric oncology patients and is often associated with recurrences and complications. We hypothesized that higher intensity of chemotherapy would be associated with these outcomes. We conducted a retrospective cohort study including all cases of primary CDI in children with malignancy in our institution for over 7 years. Intensity of chemotherapy was measured by the Intensity of Treatment Rating Scale, third edition, ranging from level 1 (minimal) to 4 (highest). Outcomes included recurrence within both 56 and 180 days, CDI-associated complications, and primary treatment failure (PTF). Risk of recurrence was compared using Cox proportional hazards regression. Among 192 patients with CDI and malignancy, 122 met inclusion criteria. CDI recurred in 27% (31/115) of patients followed for 56 days and 46% (48/104) of patients followed for 180 days. Fourteen patients (11.4%) had a CDI-associated complication, including 4 intensive care unit admissions and 3 surgical procedures, but no deaths. Ten patients (8.2%) had PTF. Although PTF and severe complications were infrequent, recurrence was common in our cohort. None of these outcomes were associated with level of treatment intensity. More research is required to assess oncologic and nononcologic risk factors for CDI recurrence, PTF, and severe CDI-associated complications.
艰难梭菌感染(CDI)在儿科肿瘤患者中很常见,且常与复发及并发症相关。我们推测化疗强度越高与这些结局相关。我们进行了一项回顾性队列研究,纳入了我们机构7年多来所有恶性肿瘤患儿原发性CDI的病例。化疗强度通过第三版治疗强度评定量表进行测量,范围从1级(最低)到4级(最高)。结局包括56天和180天内的复发、CDI相关并发症以及初始治疗失败(PTF)。使用Cox比例风险回归比较复发风险。在192例患有CDI和恶性肿瘤的患者中,122例符合纳入标准。随访56天的患者中27%(31/115)复发,随访180天的患者中46%(48/104)复发。14例患者(11.4%)发生了CDI相关并发症,包括4例入住重症监护病房和3例外科手术,但无死亡病例。10例患者(8.2%)出现初始治疗失败。尽管初始治疗失败和严重并发症不常见,但在我们的队列中复发很常见。这些结局均与治疗强度水平无关。需要更多研究来评估CDI复发、初始治疗失败和严重CDI相关并发症的肿瘤学和非肿瘤学危险因素。